Skip to content
BREAM/SIGNALS

INSIGHT BANK · 31 LIVING CARDS

Follow a question. See what changes.

Evidence, technologies, people and the next test—connected, but not confused.

Linked entity: Osimertinib · Clear

Commercializationv1 · 11.04

Why keep a drug after resistance emerges? ↗

Read article →

For which resistance profiles is it worth retaining EGFR inhibition and adding a MET inhibitor?

In phase 3 SAFFRON, 338 selected patients had median progression-free survival of 7.6 months with the combination and 5.4 months with chemotherapy.

  1. Phase 3 resultsRecorded
  2. Testing and uptakeUnverified
New question opened

Recorded phase 3 results for a combination matched to a resistance mechanism.

NEXT CHECK

Track the authorized population, testing criteria and the regimen’s place among later-line options.

Evidence: Clinical Lung Cancer ↗AstraZeneca ↗
Evidence, people & history ↗
Optional readership measurement

Allow this site to record page views, reading progress, a broad referral source and the ID of a prepared editorial post link? Reading and following cards work without this. Hosting-provider traffic logs are separate. Details & settings